Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-005234
Filing Date
2025-01-22
Accepted
2025-01-22 16:01:51
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10435
2 EXHIBIT I tm254122d1_ex-1.htm EX-99.1 6033
  Complete submission text file 0001104659-25-005234.txt   18197
Mailing Address 4 KINGSBURY AVENUE WATERTOWN MA 02472
Business Address 4 KINGSBURY AVENUE WATERTOWN MA 02472 617 607 0800
ENANTA PHARMACEUTICALS INC (Subject) CIK: 0001177648 (see all company filings)

EIN.: 043205099 | Fiscal Year End: 0930
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87373 | Film No.: 25545902
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022
Business Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022 (212) 841-4100
INTEGRATED CORE STRATEGIES (US) LLC (Filed by) CIK: 0001319244 (see all company filings)

EIN.: 980330397 | Fiscal Year End: 1231
Type: SCHEDULE 13G